MX2016009597A - Terapias para el influenzavirus a subtipo h7n9. - Google Patents

Terapias para el influenzavirus a subtipo h7n9.

Info

Publication number
MX2016009597A
MX2016009597A MX2016009597A MX2016009597A MX2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A
Authority
MX
Mexico
Prior art keywords
influenza
therapies
virus antibodies
virus
antibodies
Prior art date
Application number
MX2016009597A
Other languages
English (en)
Inventor
Chai Ning
Mcbride Jacqueline
Swem Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016009597A publication Critical patent/MX2016009597A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

La presente invención proporciona anticuerpos antiinfluenzavirus A efectivos en la unión, neutralización y tratamiento de influenzavirus A subtipo H7N9, composiciones que comprenden esos anticuerpos y métodos de uso de los mismos.
MX2016009597A 2014-01-27 2015-01-26 Terapias para el influenzavirus a subtipo h7n9. MX2016009597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931949P 2014-01-27 2014-01-27
PCT/US2015/012942 WO2015112994A1 (en) 2014-01-27 2015-01-26 H7n9 influenza a therapies with anti-h7 virus antibodies

Publications (1)

Publication Number Publication Date
MX2016009597A true MX2016009597A (es) 2016-10-13

Family

ID=52463191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009597A MX2016009597A (es) 2014-01-27 2015-01-26 Terapias para el influenzavirus a subtipo h7n9.

Country Status (10)

Country Link
US (1) US9879066B2 (es)
EP (1) EP3099710A1 (es)
JP (1) JP2017508002A (es)
KR (1) KR20160111948A (es)
CN (1) CN105934443A (es)
BR (1) BR112016015078A2 (es)
CA (1) CA2931012A1 (es)
MX (1) MX2016009597A (es)
RU (1) RU2682049C2 (es)
WO (1) WO2015112994A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP3374390A1 (en) * 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN106519027B (zh) * 2016-11-11 2019-09-17 深圳先进技术研究院 抗h7n9全人源单克隆抗体5j13及其制法与应用
CN109988236B (zh) * 2017-12-30 2022-04-01 中国科学院天津工业生物技术研究所 一种流感病毒抗体的应用
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223285A1 (en) * 2002-03-13 2003-09-29 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
JP5813629B2 (ja) * 2009-05-11 2015-11-17 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ３ｎ２を中和可能なヒト抗体及び／または抗原結合フラグメントおよびその使用
RU2500426C2 (ru) * 2010-02-27 2013-12-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1, и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1
KR101941724B1 (ko) * 2011-07-14 2019-01-23 얀센 백신스 앤드 프리벤션 비.브이. 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자
US9868952B2 (en) * 2012-07-08 2018-01-16 Sirnaomics, Inc. Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza
WO2014078268A2 (en) * 2012-11-13 2014-05-22 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
CN103450350B (zh) * 2013-07-30 2015-07-01 中国人民解放军军事医学科学院基础医学研究所 人感染h7n9禽流感表位抗原及其在免疫检测试剂中的用途

Also Published As

Publication number Publication date
EP3099710A1 (en) 2016-12-07
KR20160111948A (ko) 2016-09-27
RU2016128223A3 (es) 2018-08-13
CA2931012A1 (en) 2015-07-30
US20170114121A1 (en) 2017-04-27
CN105934443A (zh) 2016-09-07
WO2015112994A1 (en) 2015-07-30
RU2016128223A (ru) 2018-03-05
US9879066B2 (en) 2018-01-30
JP2017508002A (ja) 2017-03-23
BR112016015078A2 (pt) 2018-01-23
RU2682049C2 (ru) 2019-03-14

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
PH12017502180A1 (en) Tau-binding antibodies
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MY176855A (en) Anti-jagged1 antibodies and methods of use
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12017502207A1 (en) Tau-binding antibodies
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2022001220A (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.
NZ744340A (en) Anti-jagged1 antibodies and methods of use
TH1601002905A (th) วิธีการและองค์ประกอบสำหรับการดัดแปลงที่มีเป้าหมายของจีโนม